Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?
The main pharmacological effects of marijuana, as well as synthetic and endogenous cannabinoids, are mediated through G-protein-coupled receptors (GPCRs), including CB(1) and CB(2) receptors. The CB(1) receptor is the major cannabinoid receptor in the central nervous system and has gained increasing interest as a target for drug discovery for treatment of nausea, cachexia, obesity, pain, spasticity, neurodegenerative diseases and mood and substance abuse disorders. Evidence has accumulated to suggest that CB(1) receptors, like other GPCRs, interact with and are regulated by several other proteins beyond the established role of heterotrimeric G-proteins. These proteins, which include the GPCR kinases, beta-arrestins, GPCR-associated sorting proteins, factor associated with neutral sphingomyelinase, other GPCRs (heterodimerization) and the novel cannabinoid receptor-interacting proteins: CRIP(1a/b), are thought to play important roles in the regulation of intracellular trafficking, desensitization, down-regulation, signal transduction and constitutive activity of CB(1) receptors. This review examines CB(1) receptor-interacting proteins, including heterotrimeric G-proteins, but with particular emphasis on non-G-protein entities, that might comprise the CB(1) receptosomal complex. The evidence for direct interaction with CB(1) receptors and potential functional roles of these interacting proteins is discussed, as are future directions and challenges in this field with an emphasis on the possibility of eventually targeting these proteins for drug discovery.
Smith
Tricia H
TH
Department of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, MCV Campus, Richmond, VA 23298-0524, USA.
Sim-Selley
Laura J
LJ
Selley
Dana E
DE
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000502:physiology; D002186:Cannabinoids / Q000494:pharmacology / Q000627:therapeutic use; D002352:Carrier Proteins / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D055503:Protein Multimerization; D020239:Receptor Cross-Talk / Q000187:drug effects / Q000502:physiology*; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism
D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D002352:Carrier Proteins; C540799:Cnrip1 protein, rat; D043884:Receptor, Cannabinoid, CB1; D043562:Receptors, G-Protein-Coupled